PER

4.94%

8.5¢ percheron therapeutics limited

US deal for ATL1102, page-2

First 2 Last

Share
Profile

Follow
Uboy

4,683 Posts.

1086

27/03/21

17:25

Post #: 52086358
Share

Originally posted by George1972 ↑

To look at things from another angle, i try to put myself in others peoples position to see what may happen.

If I was the CEO of Sarepta, i would be in pure crisis mode right now.

At December 31st they had US$1.8 billion cash in the bank. The market cap has fallen from US$14bn to US$6bn.. i have US$500m in revenue with most coming from Exondys which has been on the market for 4 yrs but I have an approaching deadline to show clinical efficacy or it may get pulled.

My share price has fallen from $180 to be sitting right on key support at $75..

What if I just push forward with the exon skipping and the FDA pull my main drug?

What if Roche gazump me and take over the US rights to ATL1102 or Antisense go it alone in the US?? What if the Pfizer DMD GT beat us to the punch?? It does not look good for Sarepta under any of the above situations..

If I was Roche, i would take the US rights to ATL1102 for DMD and squeeze the life out of Sarepta and then take them over cheaply..

With $1.8bn cash in the bank and a 1 year trial for ATL1102 in the US, Sarepta would be crazy not to do a deal. It gives them a whole new story and some time to breath. Also, doing combination trials for ATL1102 and the exon skipping drugs may allow them to get the FDA to push out the deadlines to show clinical efficacy for Exondys..

All roads lead to a deal with Sarepta in the US.

Expand

Agree 100%

Throw in now the Professor Voit connection...and a combination trial makes so much sense.

How much ‘shade’ did Diamond throw at Sarepta in yesterday’s presentation?

Not so vailed message to Doug Ingram

As Waynesworld said last week, Doug just needs to get the Roche agreement out and swap the entities ...this time Sarepta paying $750m upfront.

Has all the makings of a Hot Copper ‘fantasy stick’...

Just need Wombat here plucking revenue numbers like he does on RAC forum.

.

ANP Price at posting: 19.5¢ Sentiment: Buy Disclosure: Held
20 Upvote

0 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

RCE

Recce's R327 found effective against E.coli during clinical trial

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 201 more messages in this thread...

First 2 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.5¢		Change 0.004(4.94%)		Mkt cap ! $76.63M

Open	High	Low	Value	Volume
8.1¢	8.5¢	8.1¢	$46.54K	563.7K

Buyers (Bids)

No.	Vol.	Price($)
2	164616	8.1¢

Sellers (Offers)

Price($)	Vol.	No.
8.5¢	100110	1

View Market Depth

No.	Vol.	Price($)
2	164616	0.081
3	143000	0.080
1	250000	0.079
3	71500	0.078
2	121300	0.077

Price($)	Vol.	No.
0.085	100110	1
0.087	125000	1
0.089	102263	2
0.090	146175	1
0.091	108000	1

Last trade - 15.55pm 28/06/2024 (20 minute delay)

PER (ASX) Chart

US deal for ATL1102, page-2

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

US deal for ATL1102, page-2

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News